Media stories about Zynerba Pharmaceuticals (NASDAQ:ZYNE) have been trending positive on Thursday, Accern Sentiment reports. The research group identifies negative and positive press coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Zynerba Pharmaceuticals earned a news impact score of 0.36 on Accern’s scale. Accern also assigned headlines about the company an impact score of 0 out of 100, indicating that recent press coverage is extremely unlikely to have an effect on the company’s share price in the immediate future.

Here are some of the headlines that may have impacted Accern Sentiment’s rankings:

Zynerba Pharmaceuticals (NASDAQ ZYNE) traded down 1.50% on Thursday, hitting $13.75. 449,144 shares of the company’s stock traded hands. Zynerba Pharmaceuticals has a one year low of $8.25 and a one year high of $25.95. The stock’s market cap is $182.28 million. The stock has a 50-day moving average of $17.81 and a 200-day moving average of $19.61.

Zynerba Pharmaceuticals (NASDAQ:ZYNE) last released its quarterly earnings results on Tuesday, August 1st. The company reported ($0.64) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.60) by $0.04. On average, equities analysts forecast that Zynerba Pharmaceuticals will post ($2.46) earnings per share for the current fiscal year.

Several research analysts have recently commented on the company. Cantor Fitzgerald reiterated a “buy” rating and set a $28.00 target price on shares of Zynerba Pharmaceuticals in a report on Tuesday, May 9th. Roth Capital set a $30.00 target price on Zynerba Pharmaceuticals and gave the stock a “buy” rating in a report on Saturday, May 13th. Canaccord Genuity set a $35.00 target price on Zynerba Pharmaceuticals and gave the stock a “buy” rating in a report on Saturday, May 13th. Maxim Group set a $32.00 target price on Zynerba Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, June 26th. Finally, Zacks Investment Research upgraded Zynerba Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, July 13th. Two equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $31.44.

ILLEGAL ACTIVITY NOTICE: “Zynerba Pharmaceuticals (ZYNE) Earning Favorable News Coverage, Study Finds” was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this article on another website, it was illegally copied and republished in violation of United States and international trademark and copyright law. The correct version of this article can be accessed at https://www.thecerbatgem.com/2017/08/03/zynerba-pharmaceuticals-zyne-earns-daily-media-impact-score-of-0-36-updated-updated-updated.html.

In related news, CFO James E. Fickenscher acquired 5,200 shares of the company’s stock in a transaction on Friday, May 12th. The shares were purchased at an average price of $19.82 per share, for a total transaction of $103,064.00. Following the purchase, the chief financial officer now owns 12,200 shares in the company, valued at $241,804. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Chairman Armando Anido acquired 5,000 shares of the company’s stock in a transaction on Monday, May 15th. The stock was bought at an average price of $19.70 per share, for a total transaction of $98,500.00. Following the purchase, the chairman now owns 336,012 shares in the company, valued at approximately $6,619,436.40. The disclosure for this purchase can be found here. 10.02% of the stock is currently owned by corporate insiders.

Zynerba Pharmaceuticals Company Profile

Zynerba Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing transdermal synthetic cannabinoid treatments for patients with high unmet needs. Its development pipeline includes two product candidates: ZYN002 and ZYN001. ZYN002 is a synthetic cannabidiol (CBD), which is a non-psychoactive cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system.

Insider Buying and Selling by Quarter for Zynerba Pharmaceuticals (NASDAQ:ZYNE)

Receive News & Stock Ratings for Zynerba Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynerba Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.